New Approach Using Multi-Parametric MRI and Same-Day Bladder Biopsy for Diagnosing Muscle-Invasive Bladder Cancer Compared to Standard Bladder Tumor Removal
Led by Radboud University Medical Center · Updated on 2026-01-08
360
Participants Needed
19
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two diagnostic approaches for patients suspected of having muscle-invasive bladder cancer MIBC. This trial compares the standard care method, Transurethral Resection of the Bladder Tumor TURBT, with a newer approach using multiparametric MRI mpMRI followed by a same-day cystoscopic bladder biopsy. The study aims to assess progression-free survival, time to definitive treatment, and cost-effectiveness over two years.
Participants will be randomly assigned to one of two groups one undergoing mpMRI plus same-day cystoscopic bladder biopsy, and the other receiving TURBT with blood samples taken shortly before and after the procedure. Both groups will be monitored and compared for their diagnostic outcomes and related healthcare costs.
Throughout the study, participants will have regular evaluations including assessments of progression-free survival, quality of life, healthcare costs, and circulating tumor cells before and after TURBT. The main outcome measure is progression-free survival at two years. The study involves multiple centers and aims to provide detailed information on the effectiveness and cost implications of these diagnostic strategies.
CONDITIONS
Brief Title
Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm
Research Team
A
A. G. van der Heijden, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinically suspected muscle-invasive bladder cancer (MIBC)
No lymph node or distant metastases
Written informed consent provided
You will not qualify if you...
Unable or unwilling to undergo multiparametric MRI (mpMRI)
Unfit for Transurethral Resection of the Bladder Tumor (TURBT)
Unfit for definitive treatment with curative intent
History of cancer, including bladder cancer, except non-melanoma skin cancer, prostate cancer on active surveillance, or any solid malignant tumor with at least 5 years disease-free since last treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo a multiparametric MRI plus a same-day cystoscopic bladder biopsy or a transurethral resection of the bladder tumor with blood withdrawal before and after the procedure to assess muscle invasive bladder cancer.
1 visit (in-person)
Long-term Monitoring
Duration - 2 years
Participants are monitored for progression-free survival, time to definitive treatment, quality of life, healthcare costs, and circulating tumor cells over 2 years after the diagnostic procedures.
Periodic assessments over 2 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Bladder-Sparing Treatment Approach for Large Non-Muscle-Invasive Bladder Cancer
Comparing Maximal TURBT with Chemotherapy and Immunotherapy Versus Immediate Radical Cystectomy
Phase 12 Study Evaluating Intravesical MK-3120 for High-Risk Non-Muscle Invasive Bladder Cancer After Tumor Removal
Phase 3 Study Comparing Sacituzumab Tirumotecan to Non-Platinum Chemotherapy in Advanced Urothelial Cancer
Phase 1 Study of Intratumoral ONM-501 Alone and with Cemiplimab for Advanced Solid Tumors and Lymphomas
Get Moving Trial Evaluating Home-Based Prehabilitation Exercise Using ExerciseRx App
for Bladder and Upper Tract Urothelial Cancer Patients Undergoing Surgery
Long-Term Study of Urothelial and Rare Genitourinary Tract Cancers to Understand Disease Progression and Treatment Responses
Validating a New Multiplex ELISA Urine Test for Detecting Bladder Cancer
in Adults with Microscopic Hematuria
Non-Invasive Multiplex ELISA Test to Monitor Patients with a History of Bladder Cancer
Evaluating Personalized Chemotherapy for Bladder Cancer Using Organoid Technology
A Study Comparing Organoid-Guided Drug Sensitivity and BCG Treatment
For Adults Aged 18 to 80 with Non-Muscle Invasive Bladder Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Multiparametric MRI for local staging in patients with suspected muscle-invasive bladder cancer: study protocol for a multicentre, non-inferiority randomised controlled trial (the BladParadigm study).
Sebastiaan W van Koeverden, Lisa Mc van Hoogstraten, Maarten de Rooij...